Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06943287

Pharmacist Intervention to Improve Smoking Cessation

The goal of this study is to assess the effectiveness of a remote pharmacist intervention to help smokers quit.

The main questions it aims to answer are:

* Will smokers being screened for lung cancer with low-radiation-level chest computed tomography (CT) be willing to participate in this study and talk to the pharmacist about smoking cessation? * Will those in the intervention group be more likely to report smoking cessation than those in the control group.

Participants in the intervention group will be asked to complete a baseline survey; speak with a pharmacist via phone call at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks; and complete an exit survey.

Participants in the control group will be asked to complete a baseline survey and an exit survey.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Smoking Cessation Behavior Health Behavior

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Iowa Health Care

Iowa City, Iowa, 52242, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current smoker
  • Current patient in the Lung Cancer Screening Program

Exclusion criteria

  • Unable to speak/read English
  • Unable to provide their own written informed consent

Treatment and study plan

Pharmacist intervention

Behavioral

If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.

Primary outcomes

  1. Number of Interactions with Pharmacist

    Time frame: 12 weeks

    The number of phone calls the intervention participants complete with the research pharmacist.

Secondary outcomes

  1. Number of Nicotine Replacement Therapies Used to Quit Smoking

    Time frame: 12 weeks

    The number of participants who use nicotine replacement therapies during the study.

  2. Number of Non-Medication Tool Used to Quit Smoking

    Time frame: 12 weeks

    The number of participants who use non-medication tools to quit smoking.

  3. Number of Successful Quit Attempts

    Time frame: 12 weeks

    The number of participants who have successfully quit smoking at the end of the study.

Sponsors and collaborators

Lead sponsor

University of Iowa

Other

Registry information

Official study title

A Remote Pharmacist Intervention to Improve Smoking Cessation

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 24, 2025
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.